U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403721) titled 'AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors' on Feb. 05.
Brief Summary: The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
Study Start Date: Jan. 21
Study Type: INTERVENTIONAL
Condition:
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Intervention:
DRUG: AMG 436
AMG 436...